Journal of Korean Traditional Oncology (대한암한의학회지)

Korean Association of Traditional Oncology (대한암한의학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Traditional Korean Medicine Based-Integrative Oncology of Recurrent Pancreatic Cancer

재발된 췌장암 환자의 한의 기반 통합 암 치료에 대한 증례보고

  • Han-eum, Joo (East-West Cancer Center, Daejeon Korean Medicine Hostiptal of Daejeon University) ;
  • Jae-wook, Kim (Deok-jin Korean Medical Hospital) ;
  • Ji-hye, Park (East-West Cancer Center, Seoul Korean Medicine Hostiptal of Daejeon University) ;
  • Young-min, Cho (East-West Cancer Center, Daejeon Korean Medicine Hostiptal of Daejeon University) ;
  • Hyun-sik, Seo (East-West Cancer Center, Daejeon Korean Medicine Hostiptal of Daejeon University) ;
  • Eun-ju, Ko (East-West Cancer Center, Daejeon Korean Medicine Hostiptal of Daejeon University) ;
  • So-jeong, Park (Dept. of Korean Internal Medicine, Korean Medicine Hospital of Pusan National University) ;
  • Hwa-seung, Yoo (East-West Cancer Center, Daejeon Korean Medicine Hostiptal of Daejeon University)
  • 주한음 (대전대학교 대전한방병원 동서암센터) ;
  • 김재욱 (덕진한방병원) ;
  • 박지혜 (대전대학교 서울한방병원 동서암센터) ;
  • 조영민 (대전대학교 대전한방병원 동서암센터) ;
  • 서현식 (대전대학교 대전한방병원 동서암센터) ;
  • 고은주 (대전대학교 대전한방병원 동서암센터) ;
  • 박소정 (부산대학교 한방병원 내과질환센터) ;
  • 유화승 (대전대학교 대전한방병원 동서암센터)
  • Received : 2022.10.07
  • Accepted : 2022.12.14
  • Published : 2022.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: To report recurrent pancreatic cancer treated by Korean medicine based-integrated oncology treatment, who is improved quality of life without progression of cancer Method: A 63-year-old female patient diagnosed with recurrent pancreatic cancer in April, 2022 received Chemotherapy with Korean medicine based integrative oncology treatment. Radiologic outcome was assessed by Abdomen Computed Tomography (CT) based on Response Evaluation Criteria In Solid Tumors (RECIST). Clinical outcomes were assessed by National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), Eastern Cooperative Oncology Group (ECOG), Numeric Rating Scale (NRS) Result: During 2months of treatment, Cancer size was stable in Abdominal CT. Chief complaints, Abdominal pain and dyspepsia, were improved and ECOG score was improved from grade 2 to 1. There were no toxicity on laboratory test and no side effects of grade 3 or higher on NCI-CTCAE. Conclusion: This report shows that Korean medicine based integrative oncology treatment might contribute to synergetic effect to Chemotherapy and improvement of quality of life

Keywords

Acknowledgement

이 연구는 보건복지부 한국보건산업진흥원 한의약선도기술개발사업의 지원에 의하여 이루어진 것임(과제고유번호:HI19C1046)

References

  1. Ministry of Health and Welfare, Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2019. Sejong: Ministry of Health and Welfare, 2021
  2. Riall T.S., Lillemoe K.D. Underutilization of surgical resection in patients with localized pancreatic cancer. Ann Surg. 246;181-182, 2007 https://doi.org/10.1097/SLA.0b013e31811eaa2c
  3. Dunne RF, Hezel AF. Genetics and Biology of Pancreatic Ductal Adenocarcinoma. Hematology/Oncology Clinics of North America. 29(4):595-608, 2015 https://doi.org/10.1016/j.hoc.2015.04.003
  4. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma(version1.2022), 2022
  5. Gbolahan OB, Tong Y, Sehdev A, O'Neil B, Shahda S. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study. BMC Cancer. 19(1), 2019
  6. Park JS, Yoo HS, Lee YW, Cho JH, Son CG, Cho CK. Wheel Balance Cancer Therapy in the Treatment of Metastatic Gastric Carcinoma: A Retrospective Analysis of 62 Patients. Korean J Orient Int Med 28(3)531-543, 2007
  7. Ko EJ, Myeong JS, KIM JH, Park JH, Park SJ, Lee YW, YOO HS. A Case Report of Pancreatic Cancer with Liver Metastasis Patient Treated with Integrative Cancer Treatment. J of Kor Traditional Oncology. 26(1):39-48, 2021
  8. Schwartz LH, Litiere S, de Vries E, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, Liu Y, Therasse P, Wolchok JD, Seymour L. RECIST 1.1: Update and clarification-From the RECIST committee. Eur J Cancer 62:132-137, 2016 https://doi.org/10.1016/j.ejca.2016.03.081
  9. National Cancer Institute. Common Terminology Criteria for Adverse Events(CTCAE) v.5.0, 2017. Available from https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_5.0/
  10. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5(6):649-55, 1982 https://doi.org/10.1097/00000421-198212000-00014
  11. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Guimbaud R, Becouarn Y, Adenis A, Raou JL, Gourgou-Bourgade S, Fouchardiere C, Bennouna J, Bachet JB, Kemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine. 364(19):1817-1825, 2011 https://doi.org/10.1056/NEJMoa1011923
  12. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine. 369(18):1691-1703, 2013 https://doi.org/10.1056/NEJMoa1304369
  13. Kim YJ, Seo DW, Pack KM, Jeong EH, Kim SC, Han DJ, Lee SS, Lee SK, Kim MH. The Prognostic Factors of Pancreatic Cancer Can be Different according to Clinical Stages. Korean J Gastroenterol. Mar;51(3):181-189, 2008.
  14. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557, 1996 https://doi.org/10.1097/00001813-199607000-00010
  15. Sudo K. S-1 in the treatment of pancreatic cancer. World Journal of Gastroenterology. 20(41):15110,2014
  16. Lee DE, LEE SY, Kim JS, Cho CK, Yoo HS, Choi SJ. Antitumor Effect of Hang-Am Dan(HAD) and its Ingredients on Calu6 and MCF-7 Human Cancer Cell Lines. J Korean Oriental Med 30(5):50-60, 2009
  17. Kim KS, Yoo HS, Jung TY, Lee YW, Cho CK. Case series of Advanced or Metastatic Gallbladder Cancer Patients Treated with Hang-Am-Dan. Korean J Orient Int Med. 31(3):667-674, 2010
  18. Lee NH, Yoon DH, Yoo HS, Cho JH, Son CG, Lee YW, Cho CK. Changes of Serum VEGF, bFGF levels and platelet counts in 100 Cancer Patients treated with Hang-Am-Dan. Korean J Orient Int Med 26(4):753-760, 2005
  19. Furukawa K, Shiba H, Hamura R, Haruki K, Fujiwara Y, Usuba T, Nakabayashi Y, Misawa T, Okamoto T, Yanaga K. Prognostic Factors in Patients With Recurrent Pancreatic Cancer: A Multicenter Database Analysis. Anticancer Research. 40(1):293-8, 2020 https://doi.org/10.21873/anticanres.13952
  20. Meunier L, Larrey D. Chemotherapyassociated steatohepatitis. Annals of Hepatology 19:597-601, 2020. https://doi.org/10.1016/j.aohep.2019.11.012
  21. Gangi A, Lu SC. Chemotherapy-associated liver injury in colorectal cancer. Ther Adv Gastroenterol 13:1-9, 2020
  22. Lee GY, Park CR, Cho JH, Son CG, Lee NH. The effect of Chunggan Plus Extract in Improving Liver Function: A retrospective Case Series of Eight Patients. J Int Korean Med 41(3):542-551, 2020 https://doi.org/10.22246/jikm.2020.41.3.542
  23. Lee JH, Lee J-H, Lim Y-S, Yeon JE, Song T-J, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, Yoon JH. Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology. 148(7):1383-91.e6., 2015 https://doi.org/10.1053/j.gastro.2015.02.055
  24. Chung MJ, Park JY, Bang SM, Park SW, Song SY. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Cancer Immunol Immunother 63:939-946, 2014. https://doi.org/10.1007/s00262-014-1566-3
  25. Koulouris AI, Banim P, Hart AR. Pain in Patients with Pancreatic Cancer: Prevalence, Mechanisms, Management and Future Developments. Digestive Diseases and Sciences. 62(4):861-870, 2017 https://doi.org/10.1007/s10620-017-4488-z
  26. Staats PS, Hekmat H, Sauter P, Lillemoe K. The Effects of Alcohol Celiac Plexus Block, Pain, and Mood on Longevity in Patients With Unresectable Pancreatic Cancer: A Double-blind, Randomized, Placebo-controlled Study. Pain Medicine. 2(1):28-34, 2001 https://doi.org/10.1046/j.1526-4637.2001.002001028.x
  27. Oriental Medical Schools Herbology Compilation Committee. Herbology. Seoul:Yeongrimsa. 311-2, 2009
  28. Yoon MJ, Cho NK, Lee YR, Choi HS, Kim SM, Kim KS. A Case Report of a Non-small Cell Lung Cancer Patient Metastasis to Vertebra with Cancer Pain Improved by Traditional Korean medicine including Aconitum Ciliare Decaisne Pharmacopuncture. J of Kor Traditional Oncology 24(2):33-41, 2019.
  29. He Y, Guo X, May BH, Zhang AL, Liu Y, Lu C, Mao JJ, Xue CC, Zhang H. Clinical Evidence for Association of Acupuncture and Acupressure With Improved Cancer Pain. JAMA Oncology. 6(2):271, 2020
  30. Lee KO, Kuk YB, Yun YG. Effects of Jakyakgamchotang extract on the Analgesic effect in Mice. The Korean Journal of Oriental Medical Prescription 11(3):161-170, 2003.